摘要
Prostate cancer is a common cancer among men world-wide.Large-scale clinicalstudies of the 1,000 mg daily dos-ing of abiraterone acetate(AA)have confirmed its antitu-mor efficacy in patients with metastatic hormone-sensitiveprostate cancer(mHSPC)or metastatic castration-resistantprostate cancer(mCRPC),regardless of their cancer’sresponse to androgen deprivation therapy(ADT)or treat-ment duration.However,this dosage was indirectly jus-tified based on the absence of dose-limiting toxicities(DLTs)in prior phase I dose-escalation trials,where aplateau in the increase of upstream steroids relating tosecondary mineralocorticoid excess was observed at dosesgreater than 750 mg and up to 2,000 mg daily[1,2].Notably,prostate specific antigen(PSA)levels declined atall investigated doses(250 to 1,000 mg)[1,2].
基金
funded by Joseph Lim Boon Tiong UrologyCancer Research(Grant:A-0002678-01-00).
